Novartis AG ADR (NVS)vsProtalix Biotherapeutics Inc (PLX)
NVS
Novartis AG ADR
$153.67
-0.26%
HEALTHCARE · Cap: $290.96B
PLX
Protalix Biotherapeutics Inc
$2.37
+2.16%
HEALTHCARE · Cap: $190.15M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 74124% more annual revenue ($56.69B vs $76.38M). NVS leads profitability with a 22.5% profit margin vs 20.1%. PLX trades at a lower P/E of 12.4x. PLX earns a higher WallStSmart Score of 60/100 (C+).
NVS
Buy51
out of 100
Grade: C-
PLX
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-70.9%
Fair Value
$92.73
Current Price
$153.67
$60.94 premium
Intrinsic value data unavailable for PLX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 31.8%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Strong operational efficiency at 62.6%
Revenue surging 233.7% year-over-year
Every $100 of equity generates 23 in profit
Keeps 20 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Attractively priced relative to earnings
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Smaller company, higher risk/reward
Weak financial health signals
Earnings declined 1.0%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 31.8%.
Bull Case : PLX
The strongest argument for PLX centers on Operating Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 20.1% and operating margin at 62.6%. Revenue growth of 233.7% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PLX
The primary concerns for PLX are Market Cap, Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
NVS profiles as a value stock while PLX is a growth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
PLX is growing revenue faster at 233.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
PLX scores higher overall (60/100 vs 51/100), backed by strong 20.1% margins and 233.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Protalix Biotherapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?